Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 104Neoplasms 11Neoplasm Metastasis 11Glioma 8Ovarian Neoplasms 6Melanoma 6Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Liposarcoma 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Recurrence 4Medulloblastoma 4Endometrial Neoplasms 4Diffuse Intrinsic Pontine Glioma 4Colorectal Neoplasms 4Breast Diseases 4Brain Neoplasms 4Neuroblastoma 3Neoplasms by Site 3Lymphoma 3Hereditary Sensory and Autonomic Neuropathies 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Astrocytoma 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2

Interventions

Fulvestrant 6Letrozole 4Capecitabine 4exemestane 3dalpiciclib 3Trastuzumab 3Docetaxel 3Anastrozole 3ribociclib 2palbociclib 2fluzoparib 2apatinib 2Irinotecan 2Gemcitabine 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1nirogacestat 1margetuximab 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1Tamoxifen 1Rogaratinib 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Cancer Metastatic × ribociclib × Clear all
NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Samsung Medical Center

Phase 2 Not yet recruiting
272 enrolled
Breast

Breast Cancer Metastatic

NCT03555877 2023-07-07

AMICA

GBG Forschungs GmbH

Phase 2 Completed
56 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡